Six posters on clinical experience with biosimilar infliximab at ECCO congress

February 20, 2015 1:34 PM

Celltrion Healthcare has announced data demonstrating that the world’s first biosimilar monoclonal antibody (mAb) infliximab is an effective treatment option for patients with the chronic debilitating autoimmune diseases, Crohn’s disease (CD) and ulcerative colitis (UC).

Clinical experience of biosimilar infliximab in 332 patients with inflammatory bowel disease (IBD) is being presented in six posters and a satellite symposium at ECCO 2015 showing that the treatment is effective and safe in these patients. The safety and efficacy of biosimilar infliximab in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have previously been demontrated in two pivitol clinical trials, PLANETAS and PLANETRA. Biosimilar infliximab, developed by Celltrion, Inc, is approved by the EMA for treatment of eight autoimmune diseases, including adult and pediatric CD and UC.

Six posters show clinical experience with biosimilar infliximab
Data from six prospective observational trials, totalling 258 patients from Europe and South Korea, show that the biosimilar infliximab is an effective and well-tolerated treatment for patients with CD and UC.

In one study of 106 patients with CD or UC, the clinical response to the treatment at 8 weeks was ?87% in patients who had not been treated with anti-tumor necrosis factor (anti-TNF) therapy before and ?67% in patients who had switched from another anti-TNF therapy. Another study, in which data was collected prospectively on 90 patients with CD or UC, demonstrated decreases in internationally recognized scores of disease activity after 6 weeks of treatment with the biosimilar mAb infliximab, CDAI and pMAYO score.

Case report from Norway
At a satellite symposium session, Jørgen Jahnsen, Professor of Gastroenterology at the University of Oslo, Norway, reported on his clinical experience of treating CD and UC patients with biosimilar mAb infliximab. A reduction in disease activity at week fourteen was reported in 74 IBD patients (44 CD and 30 UC): after three infusions of biosimilar infliximab, there was a significant reduction in HBI, calprotectin and CRP in CD patients, and in partial MAYO score, Simple AI, calprotectin and CRP in UC patients.

Stanley Hong, President of Celltrion Healthcare, said: “The data presented at ECCO’s 2015 congress support the EMA’s decision to approve the biosimilar infliximab for the treatment of Crohn’s disease and ulcerative colitis in the EU based on extrapolation of the clinical data in rheumatologic diseases which demonstrated comparable efficacy and safety to its reference medicinal product. We are conducting prospective observational and registry trials as part of pharmacovigilance in the EU and South Korea to monitor the safety of the biosimilar infliximab.”

 

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!